AZN: AstraZeneca PLC
About
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Current Value
$63.891 Year Return
Current Value
$63.891 Year Return
Key Details
Market Cap
$197.82B
P/E Ratio
30.44
1Y Stock Return
-0.75%
1Y Revenue Growth
13.81%
Dividend Yield
2.11%
Price to Book
4.9
Strategies that include AZN
Stock's related to AZN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NVS | 49.43% | $202.05B | +7.15% | 3.64% |
| SNY | 36.95% | $120.34B | +3.11% | 4.25% |
| BUD | 34.82% | $98.10B | -9.62% | 1.60% |
| UL | 34.81% | $143.25B | +21.40% | 3.25% |
| YORW | 33.64% | $514.17M | -3.87% | 2.37% |
| GSK | 33.60% | $68.24B | -5.43% | 4.71% |
| CE | 33.58% | $7.89B | -44.64% | 3.89% |
| O | 33.58% | $50.04B | +6.78% | 5.49% |
| BIO | 33.44% | $8.98B | +4.73% | 0.00% |
| ETR | 33.30% | $32.14B | +49.00% | 3.05% |
| BATRK | 33.13% | $2.51B | +13.03% | 0.00% |
| NNN | 33.00% | $8.14B | +10.88% | 5.30% |
| OGE | 33.00% | $8.67B | +24.45% | 3.88% |
| NTST | 32.86% | $1.30B | +2.31% | 5.22% |
| ZBH | 32.76% | $22.09B | -1.73% | 0.87% |
| TFX | 32.72% | $8.97B | -10.85% | 0.71% |
| ABT | 32.70% | $203.16B | +14.93% | 1.88% |
| SPGI | 32.50% | $155.87B | +21.40% | 0.72% |
| GMAB | 32.14% | $13.02B | -33.87% | 0.00% |
| DEO | 31.95% | $66.22B | -15.77% | 3.46% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TPST | -0.04% | $37.75M | -77.59% | 0.00% |
| DOCS | -0.04% | $9.62B | +114.35% | 0.00% |
| RPTX | 0.11% | $122.43M | -39.50% | 0.00% |
| BYRN | 0.12% | $479.70M | +295.19% | 0.00% |
| CCRN | -0.13% | $341.35M | -50.81% | 0.00% |
| FIVE | -0.14% | $4.65B | -54.68% | 0.00% |
| NLOP | -0.15% | $458.04M | +94.60% | 0.00% |
| IMXI | -0.20% | $651.21M | -1.55% | 0.00% |
| MSFT | 0.21% | $3.11T | +11.99% | 0.54% |
| TSM | 0.22% | $983.61B | +92.73% | 1.17% |
| KIRK | 0.24% | $20.86M | -17.19% | 0.00% |
| AMAT | 0.24% | $139.58B | +13.44% | 0.85% |
| NNE | -0.25% | $833.66M | +531.50% | 0.00% |
| CDLX | 0.32% | $178.39M | -54.00% | 0.00% |
| ATGE | -0.34% | $3.29B | +55.26% | 0.00% |
| IGMS | 0.36% | $567.29M | +67.37% | 0.00% |
| CASI | -0.39% | $71.56M | -6.32% | 0.00% |
| ADBE | 0.41% | $219.93B | -18.23% | 0.00% |
| PSTG | -0.43% | $16.35B | +36.41% | 0.00% |
| GAN | -0.46% | $83.39M | +21.19% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UTI | -21.34% | $1.07B | +73.54% | 0.00% |
| HCKT | -16.99% | $838.57M | +36.65% | 1.45% |
| ALAB | -16.76% | $15.10B | +164.39% | 0.00% |
| QNST | -16.54% | $1.19B | +93.14% | 0.00% |
| AMSF | -15.17% | $1.11B | +22.66% | 2.52% |
| EIG | -14.45% | $1.30B | +38.83% | 2.25% |
| VMEO | -14.43% | $1.07B | +75.96% | 0.00% |
| RDDT | -14.28% | $24.08B | +303.41% | 0.00% |
| CFLT | -14.16% | $9.28B | +49.05% | 0.00% |
| ARM | -13.96% | $139.85B | +126.83% | 0.00% |
| SMLR | -13.84% | $336.72M | +25.48% | 0.00% |
| HMN | -13.79% | $1.65B | +24.56% | 3.34% |
| ARIS | -13.46% | $763.08M | +214.02% | 1.56% |
| GEO | -13.39% | $3.97B | +204.07% | 0.00% |
| APO | -13.37% | $132.62B | +91.28% | 1.09% |
| RJF | -13.12% | $33.06B | +55.96% | 1.11% |
| BKNG | -12.92% | $164.72B | +58.25% | 0.53% |
| PLTR | -12.92% | $143.47B | +218.08% | 0.00% |
| VERX | -12.80% | $7.99B | +89.70% | 0.00% |
| HUSA | -12.45% | $16.69M | -11.56% | 0.00% |
ETF's related to AZN
News
Yahoo
UBS upgraded AstraZeneca (AZN) to Neutral from Sell with an unchanged price target of 11,300 GBp. The firm cites the stock’s 24% decline over the past three months amid China government investigations and “disappointing” data on Dato-DXd lung potential for the upgrade. While significant China uncertainty, but wholesale loss of AstraZeneca’s franchise seems unlikely, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaki
Yahoo
Berenberg lowered the firm’s price target on AstraZeneca (AZN) to EUR 140 from EUR 150 and keeps a Buy rating on the shares. Within the space of a year, AstraZeneca’s share price has given up all of its gains following further disappointment in Dato-DXd lung cancer data and elevated investor fears regarding employee investigations in China, the analyst tells investors in a research note. However, the firm says the company’s pipeline prospects are largely unchanged and the China impact appears to
SeekingAlpha
Absci Corporation has secured key partnerships but lacks advanced assets. Find out why ABSI stock is still a speculative investment despite its AI potential.
Yahoo
WILMINGTON, Del., November 20, 2024--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date.
Yahoo
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
Yahoo
(Bloomberg) -- AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its bearish analyst ratings.Most Read from BloombergParis to Replace Parking Spaces With TreesTrump Promises Could Have Seismic Impact on Washington EconomyNew York’s Transit Agency Approves $9 Congestion TollTokyo’s Scorching Summers Focus Public Anger Against Tree CuttingNY Congestion Pricing Survived a Pause. Here’s What Could Kill ItShares in the London-listed drug maker
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.